SCHEMBL6700818

SCHEMBL6700818

O=C(O)c1ccc2c(c1)nc(-c1ccc(OCc3cc(C(=O)N4CCCC4)ccc3-c3ccc(Cl)cc3)cc1F)n2C1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
NR1H4 Q96RI1 11/20 0.41
VDR P11473 5/20 0.41
HPGD P15428 5/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
CYP3A4 P08684 3/20 0.39
CYP2D6 P10635 3/20 0.39
CYP2C9 P11712 3/20 0.39
PKM P14618 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6699127 1.00 L3MBTL1 (0.43) L3MBTL1NR1H4VDRHPGDNPC1
Hydrochloric Acid SCHEMBL5512627 0.99 L3MBTL1 (0.42) L3MBTL1NR1H4VDRHPGDNPC1
Hydrochloric Acid SCHEMBL5515021 0.99 L3MBTL1 (0.42) L3MBTL1NR1H4VDRHPGDNPC1
SCHEMBL6700684 0.95 L3MBTL1 (0.41) L3MBTL1NR1H4VDRCYP3A4CYP2D6
SCHEMBL6700695 0.95 NR1H4 (0.41) L3MBTL1NR1H4VDRHPGDNPC1
SCHEMBL6695321 0.95 L3MBTL1 (0.41) L3MBTL1NR1H4VDRNPC1RAB9A
SCHEMBL12204670 0.95 L3MBTL1 (0.42) L3MBTL1NR1H4VDRCYP3A4CYP2D6
Hydrochloric Acid SCHEMBL5513868 0.95 L3MBTL1 (0.41) L3MBTL1NR1H4VDRCYP3A4CYP2D6
SCHEMBL14383819 0.94 L3MBTL1 (0.40) L3MBTL1NR1H4VDRCYP3A4CYP2D6
SCHEMBL5509722 0.94 L3MBTL1 (0.48) L3MBTL1NR1H4VDRCYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040082635-A1 Viricide against hepatitis virus; polymerase inhibitor JAPAN TOBACCO INC. (JP) 2004-04-29 US claimed
EP-1400241-A1 FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2004-03-24 EP claimed
US-7285551-B2 Fused-ring compounds and use thereof as drugs JAPAN TOBACCO INC. (JP) 2007-10-23 US disclosed
US-7285551-B2 Fused-ring compounds and use thereof as drugs JAPAN TOBACCO INC. (JP) 2007-10-23 US disclosed
US-20040082635-A1 Viricide against hepatitis virus; polymerase inhibitor JAPAN TOBACCO INC. (JP) 2004-04-29 US disclosed
EP-1400241-A1 FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2004-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082635-A1 Viricide against hepatitis virus; polymerase inhibitor HAVCR2, ZC3HAV1, POLR1C L3MBTL1 3799/4885NR1H4 484/4885VDR 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.